MedTrace Logo

Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars

NCT02772289 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-05-07

No results posted yet for this study

Summary

The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar.

Conditions

  • Cicatrix

Interventions

BIOLOGICAL

Mesenchyme Stem Cells low-dose group

Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.

BIOLOGICAL

Mesenchyme Stem Cells high-dose group

Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.

BIOLOGICAL

Placebo

Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.

Sponsors & Collaborators

  • Maternal and Child Health Hospital of Foshan

    lead OTHER

Principal Investigators

  • Zhengping Liu, MD · Maternal and Child Health Hospital of Foshan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-09-30
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772289 on ClinicalTrials.gov